Nurix therapeutics announces presentations at the american association for cancer research (aacr) 2023 annual meeting

Nurix to report additional preclinical data for its targeted btk degraders nx-2127 and nx-5948 nurix to report additional preclinical data for its targeted btk degraders nx-2127 and nx-5948

NRIX Ratings Summary

NRIX Quant Ranking